dihydroergotamine mesylate
dihydroergotamine mesylate is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand names including Dihydroergotamine Mesylate, dihydroergotamine mesylate. Available dosage forms: spray, injection, solution.
Drug Details
- Generic Name
- dihydroergotamine mesylate
- Brand Names
- Dihydroergotamine Mesylate, dihydroergotamine mesylate
- Application Number
- NDA020148
- Sponsor
- Oceanside Pharmaceuticals
- NDC Codes
- 2
- Dosage Forms
- SPRAY, INJECTION, SOLUTION
- Routes
- NASAL, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
- Active Ingredients
- DIHYDROERGOTAMINE MESYLATE
Indications and Usage
1 INDICATIONS AND USAGE ATZUMI is indicated for the acute treatment of migraine with or without aura in adults. ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine. ATZUMI is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.